Lino Tavares,Ihor Shevchuk,Mark Alfonso,Geraldine Marcenyac,Kirti H. Valia
申请号：
US10493002
公开号：
US08496960B2
申请日:
2002.10.23
申请国别(地区):
US
年份:
2013
代理人:
摘要：
A method of effectively treating benign prostatic hypertension in humans is achieved by administering amorphous terazosin via a transdermal formulation. Preferably, the transdermal formulation is applied to the skin of the patient and maintained in contact with the skin for at least about 24 hours, and preferably for about 3 to about 8 days.
